Mabwell (Shanghai) Bioscience Co., Ltd. (Mabwell-B) filed its Monthly Return for Equity Issuers for the period ended 30 June 2026, confirming stable capital structure and full compliance with Hong Kong Stock Exchange public-float rules.

Total authorised share capital remained unchanged at 446.73 million shares with a par value of RMB 1 each, comprising: • 47.13 million H shares listed in Hong Kong • 399.60 million A shares listed on the Shanghai Stock Exchange

Issued share capital showed no movement during the month: • H-share count held at 47.13 million, with zero treasury shares. The company affirmed that the public float exceeds the 5 % minimum threshold required for PRC issuers with dual listings. • A-share count stayed at 398.41 million issued shares, with 1.19 million shares held in treasury; total A shares outstanding remained 399.60 million.

The company reported no new share options, warrants, convertible instruments, or other equity-linked agreements during the period.

Mabwell’s board and joint company secretary Wang Hefei confirmed that all applicable listing rules, regulatory requirements, and corporate authorisations were satisfied for the reporting month.